Romosozumab
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteogenesis Imperfecta
Conditions
Osteogenesis Imperfecta
Trial Timeline
Jan 21, 2021 → Mar 30, 2023
NCT ID
NCT04545554About Romosozumab
Romosozumab is a phase 1 stage product being developed by Amgen for Osteogenesis Imperfecta. The current trial status is completed. This product is registered under clinical trial identifier NCT04545554. Target conditions include Osteogenesis Imperfecta.
What happened to similar drugs?
1 of 7 similar drugs in Osteogenesis Imperfecta were approved
Approved (1) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06079476 | Approved | Completed |
| NCT04545554 | Phase 1 | Completed |
| NCT01833754 | Phase 1 | Completed |
| NCT01588509 | Phase 1 | Completed |
Competing Products
16 competing products in Osteogenesis Imperfecta
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide (FORTEO) + Placebos | Eli Lilly | Approved | 43 |
| Zoledronic Acid | Novartis | Phase 2 | 35 |
| Zoledronic Acid | Novartis | Phase 2 | 35 |
| Zoledronic Acid | Novartis | Phase 3 | 40 |
| Romosozumab + Bisphosphonate | Amgen | Phase 3 | 47 |
| Denosumab | Amgen | Phase 3 | 32 |
| Denosumab + Alternative osteoporosis medications | Amgen | Phase 3 | 32 |
| Fresolimumab | Sanofi | Phase 1 | 29 |
| SAR439459 + Placebo | Sanofi | Phase 1 | 21 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 29 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2/3 | 36 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2 | 21 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 21 |
| setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 38 |
| setrusumab + zoledronic acid (optional) | Ultragenyx Pharmaceutical | Phase 2 | 29 |
| Bisphosphonate + Setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 38 |